Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Transformative advances in vision research: It’s the science | Ophthalmology Times
(Image Credit: AdobeStock/kkolosov) As part of Ophthalmology Times’ 50th anniversary celebration, leaders in the field are reflecting on the transformative role of science and research in advancing eye care. Deborah A. Ferrington, PhD—chief scientific officer and the Stephen J. Ryan–Arnold…
What if? Ophthalmology without OCT – Part 4 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
Throwback Series: Learning to read the patient, not just the eye | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
From lab to clinic: Advancing ophthalmic technology | Ophthalmology Times
Emerging diagnostic and surgical technologies are enhancing precision, improving efficiency, and shaping the future of patient care in ophthalmology. (Image credit: AdobeStock/Olivier Le Moal) As ophthalmic technology continues to advance, new diagnostic and surgical devices are redefining precision, efficiency, and…
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability,…
Eli Lilly to acquire Adverum Biotechnologies | Ophthalmology Times
Image credit: AdobeStock/jozefmicic The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies. The companies noted that this definitive agreement will include Adverum’s lead candidate, Ixo-vec. Adverum and Lilly’s merger…
Positive phase 2 data for neoadjuvant darovasertib offers hope for unmet need in uveal melanoma | Ophthalmology Times
Image credit: AdobeStock/Christoph Burgstedt Positive results from the ongoing Phase 2 OptimUM-09 trial are encouraging for the treatment of uveal melanoma (UM). According to the press release from IDEAYA Biosciences, the developers of this therapeutic candidate, “there are currently no…
Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times
(Image Credit: AdobeStock) The structural differences among newer second-generation anti-VEGF agents—and their implications for clinical efficacy and treatment durability—were the focus of a recent Ophthalmology Times Case-Based Roundtable®. The discussion also highlighted real-world experiences and evidence regarding extended treatment intervals…
What if? Ophthalmology without OCT – Part 3 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
Throwback Series: From epidemic to innovation in corneal surgery | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…